Prolonged Duration of Therapy Is Associated With Improved Survival in Patients Treated for Relapsed/Refractory Multiple Myeloma in Routine Clinical Care in the United States

Despite the emerging paradigm favoring continuous therapy, we report that in routine clinical care, myeloma patients at first relapse frequently discontinue treatment before progression, resulting in duration of therapy that is significantly shorter than time to next therapy. We further describe the association between length of therapy in second line and improved overall survival in patients with relapsed/refractory multiple myeloma.

Source: Clinical Lymphoma, Myeloma and Leukemia - January 5, 2018 Category: Hematology Authors: Parameswaran Hari, Dorothy Romanus, Antonio Palumbo, Katarina Luptakova, Robert M. Rifkin, Linh Mai Tran, Aditya Raju, Eileen Farrelly, Stephen J. Noga, Marlo Blazer, Ajai Chari Tags: Original Study Source Type: research